Latest News

1 December 2014

New Data Suggest Treatment Effect on Cognition Leads to the Treatment Effect on Function in Patients with Mild Alzheimer’s Disease

Eli Lilly and Company announced results from new analyses of two Phase 3 trials evaluating the relationship between cognitive and functional treatment effects in patients with mild Alzheimer’s disease. Based on post-hoc analyses of the Phase 3 trials, the findings suggested that cognitive deficits were more apparent than functional deficits in mild Alzheimer’s disease. The apparent treatment effect on cognition based on these analyses led to the apparent treatment effect on function.

Pages

Subscribe to Latest News